Aggressive Squamous Cell Carcinoma of the Oral Tongue in a Woman With Metastatic Giant Cell Tumor Treated With Pegylated Liposomal Doxorubicin

Abstract

An instance of squamous cell carcinoma resulting from long-term treatment with pegylated liposomal doxorubicin in a woman with no risk factors for this malignancy is reported.

Squamous Cell Carcinoma of the Oral Cavity in a Woman With a 9-Year History of Ovarian Cancer: Is Exposure to Pegylated Liposomal Doxorubicin a Factor?

“…We are reporting the case of a platinum-sensitive patient (interval free: 29 months) who has developed moderately differentiated squamous cell carcinoma (SCC) of the oral cavity after exposure to PLD. No major risks for SCC were found.There was no history of smoking or alcohol consumption, and the neoplastic tissue was negative for human papillomavirus as well as for p16 expression.The cumulative dose of PLD was 683 mg/m 2 , which is considerably lower than those of 11 patients reported in literature [1][2][3][4][5][6] with doses ranging from 750 mg/m 2 to more than 3,000 mg/m 2 , although the latter was administered over a remarkable period of time (5 years).…”

Squamous Cell Carcinomas of the Tongue and Oral Cavity as Secondary Malignancies: What Factors Are Implicated?

“…As noted by Bonomi et al [15], familial adenomatous polyposis (FAP) patients have also been linked to secondary malignancies arising in the pancreas and thyroid, but to date not to oral SCCs. As for giant cell tumors of bone [19], no consistent genetic alterations have emerged, although downregulation of the RUNX3 tumor suppressor gene located in 1p36 has been implicated [20].…”